Mitsubishi Tanabe Pharma America Presents Real-World Data on RADICAVA® (edaravone) at 2022 American Academy of Neurology Annual Meeting
Analysis Suggests Use of RADICAVA IV is Associated with Improved Survival in People with ALS JERSEY CITY, N.J., April 4, 2022 — Mitsubishi Tanabe Pharma America, Inc. (MTPA) today…